Mankind Pharma Limited — Others, 03-04-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Mankind Pharma has announced a board meeting to discuss a certificate received from KFin Technologies for the quarter ended March 31, 2025. Notably, there were no requests for share dematerialization or rematerialization during this period, which indicates stability in shareholder activity. This stability could lead to a positive outlook among investors, as it reflects confidence in the company's share management and investor engagement. The absence of any need for changes suggests a steady operational environment. Overall, this update may reinforce investor sentiment regarding Mankind Pharma's governance.